Reviewer's report

**Title:** Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

**Version:** 3  **Date:** 21 January 2009

**Reviewer:** Paresh Dandona

**Reviewer’s report:**

The paper is much improved. However, the conclusion that the authors draw about the inadequacy of the mononuclear cell as a target for the study of inflammation is not appropriate. Inflammation is a systemic process and involves several organ systems, each with its own characteristic inflammatory products. It is not necessary that all will be reflected in each cell or organ. Thus, CRP and SAA are products of the liver and will not be expressed in MNC. The authors need to take this into their consideration. Furthermore, ROS generation, P47phox, NFkB binding, IkB# expression, AP-1 binding, Egr-1 binding and expression are all observed in the MNC. Furthermore, MNC is not only a cellular fraction containing inflammatory cells but it is also easily accessible.

I have no vested interest in supporting the MNC but there is no question that this cell has contributed a lot to scientific investigation and discovery. It is appropriate to point to its limitations but not to reject it.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare I have no competing interests